Genesis Healthcare Inc. Stock
Price
Target price
-
-
-
-
-
?32.07
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Genesis Healthcare Inc. Stock
Genesis Healthcare Inc. is currently one of the favorites of our community with 7 Buy predictions and no Sell predictions.
Based on the current price of 0.38 € the target price of 32 € shows a potential of 8321.05% for Genesis Healthcare Inc. which would more than double the current price.
Pros and Cons of Genesis Healthcare Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Genesis Healthcare Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Genesis Healthcare Inc. | - | - | - | - | - | - | - |
| Capital Senior Living Corp. | -0.690% | -10.063% | -11.180% | 36.190% | 5.926% | - | - |
| Healthstream Inc. | 0.000% | 3.846% | 22.727% | -11.475% | 10.769% | -3.571% | 0.935% |
| Evolent Health Inc | 0.000% | 6.918% | 6.250% | -48.092% | -0.585% | -88.194% | - |
Comments
Gen Digital (GEN) was upgraded by Wall Street Zen from "hold" to "buy".
Show more
Ratings data for GEN provided by MarketBeat
Gen Digital (GEN) was upgraded by Jefferies Financial Group Inc. from "hold" to "strong-buy".
Show more
Ratings data for GEN provided by MarketBeat
Gen Digital (NASDAQ:GEN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for GEN provided by MarketBeat
News
Cellebrite DI Eyes AI, Cloud and FedRAMP as Digital Investigations Demand Grows
Cellebrite DI (NASDAQ:CLBT) executives said the company is seeing broader customer adoption of its digital investigations platform, with artificial intelligence, cloud migration and U.S. federal
Cellebrite DI Sees Federal Rebound as AI, Defense Tools Fuel New Growth
Key Points
- Interested in Cellebrite DI Ltd.? Here are five stocks we like better.
- Federal demand is rebounding after weakness in 2025, when Cellebrite’s U.S. federal business was essentially
Cellebrite DI Q1 Earnings Call Highlights
Cellebrite DI (NASDAQ:CLBT) reported first-quarter 2026 results that management said met or exceeded the high end of its guidance for annual recurring revenue and adjusted EBITDA, while executives